Your browser doesn't support javascript.
loading
Phase II study of eribulin in combination with gemcitabine for the treatment of patients with locally advanced or metastatic triple negative breast cancer (ERIGE trial). Clinical and pharmacogenetic results on behalf of the Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC).
Pellegrino, B; Cavanna, L; Boggiani, D; Zamagni, C; Frassoldati, A; Schirone, A; Caldara, A; Rocca, A; Gori, S; Piacentini, F; Berardi, R; Brandes, A A; Foglietta, J; Villa, F; Todeschini, R; Tognetto, M; Naldi, N; Bortesi, B; Montemurro, F; Ardizzoni, A; Boni, L; Musolino, A.
Affiliation
  • Pellegrino B; Medical Oncology and Breast Unit, University Hospital of Parma, Parma, Italy; Italian Oncology Group for Clinical Research (GOIRC), Parma, Italy; Department of Medicine and Surgery, University of Parma, Parma, Italy.
  • Cavanna L; Hospital of Piacenza, Piacenza, Italy.
  • Boggiani D; Medical Oncology and Breast Unit, University Hospital of Parma, Parma, Italy; Italian Oncology Group for Clinical Research (GOIRC), Parma, Italy.
  • Zamagni C; SSD Oncologia Medica Addarii, Policlinico S.Orsola-Malpighi, Bologna, Italy.
  • Frassoldati A; Italian Oncology Group for Clinical Research (GOIRC), Parma, Italy; Medical Oncology Unit, University Hospital of Ferrara, Ferrara, Italy.
  • Schirone A; Medical Oncology Unit, University Hospital of Ferrara, Ferrara, Italy.
  • Caldara A; Medical Oncology Unit, Ospedale Santa Chiara, Trento, Italy.
  • Rocca A; Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola (FC), Italy.
  • Gori S; Sacro Cuore-Don Calabria Hospital, Negrar (VR), Italy.
  • Piacentini F; Medical Oncology Unit, University Hospital of Modena, Modena, Italy.
  • Berardi R; Ancona University Hospital, Ancona, Italy.
  • Brandes AA; Department of Medical Oncology, Azienda USL, Bologna, Italy.
  • Foglietta J; Hospital of Perugia, Perugia, Italy.
  • Villa F; Hospital of Lecco, Lecco, Italy.
  • Todeschini R; Italian Oncology Group for Clinical Research (GOIRC), Parma, Italy.
  • Tognetto M; Oncologia Medica, Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
  • Naldi N; Medical Oncology and Breast Unit, University Hospital of Parma, Parma, Italy.
  • Bortesi B; Medical Oncology and Breast Unit, University Hospital of Parma, Parma, Italy.
  • Montemurro F; Multidisciplinary Oncology Outpatient Clinic, Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Italy.
  • Ardizzoni A; Oncologia Medica, Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
  • Boni L; Clinical Epidemiology Unit, IRCCS Ospedale Policlinico San Martino, Genoa, Italy.
  • Musolino A; Medical Oncology and Breast Unit, University Hospital of Parma, Parma, Italy; Italian Oncology Group for Clinical Research (GOIRC), Parma, Italy; Department of Medicine and Surgery, University of Parma, Parma, Italy. Electronic address: antoninomusolino@hotmail.com.
ESMO Open ; 6(1): 100019, 2021 02.
Article in En | MEDLINE | ID: mdl-33399082
Subject(s)
Key words
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Triple Negative Breast Neoplasms Type of study: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Female / Humans Language: En Journal: ESMO Open Year: 2021 Document type: Article
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Triple Negative Breast Neoplasms Type of study: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Female / Humans Language: En Journal: ESMO Open Year: 2021 Document type: Article